The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database.
Tomoyuki KoguchiSei NaitoShingo HatakeyamaKazuyuki NumakuraYumina MutoRenpei KatoTakahiro KojimaYoshihide KawasakiKento MorozumiSyuya KandoriSadafumi KawamuraHiroyuki NishiyamaAkihiro ItoTomonori HabuchiWataru ObaraChikara OhyamaNorihiko TsuchiyaYoshiyuki KojimaPublished in: Cancer medicine (2023)
The results showed that the efficacy of molecular-targeted agents as first-line therapy was similar oncological outcomes between metastatic nccRCC and ccRCC in Japanese patients. TKIs may be more effective than mTORIs in metastatic nccRCC patients. Nivolumab administration might also be as effective in nccRCC patients as in ccRCC patients in Japanese population.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- small cell lung cancer
- squamous cell carcinoma
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- prostate cancer
- stem cells
- emergency department
- metabolic syndrome
- mesenchymal stem cells
- patient reported outcomes
- adipose tissue
- single molecule
- cancer therapy
- minimally invasive
- cell therapy